Motexafin gadolinium (MGd) combined with whole-brain irradiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase 3 trials Conference

Shapiro, WR, Mehta, MP, Patchell, RA et al. (2006). Motexafin gadolinium (MGd) combined with whole-brain irradiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase 3 trials . NEURO-ONCOLOGY, 8(4), 489-489.

Industry Collaboration International Collaboration

cited authors

  • Shapiro, WR; Mehta, MP; Patchell, RA; Glantz, MJ; Recht, L; Sur, R; Fortin, A; Ung, Y; Souhami, L; Phan, S; Smith, JA; Renschler, MF

sustainable development goals

authors

date/time interval

  • September 14, 2006 -

publication date

  • October 1, 2006

webpage

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • Vienna, AUSTRIA

Conference

  • 7th Congress of the European-Association-for-Neuro-Oncology (EANO)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 489

end page

  • 489

volume

  • 8

issue

  • 4